Silke Retlich - Concepedia

Author

Silke Retlich

Boehringer Ingelheim (Germany)

Also Known As

S. Retlich, Silke Retlich

Publications

687

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)University of Bonn Boehringer Ingelheim (United Kingdom)Metrum Research Group (United States)Boehringer Ingelheim (United States)

About

Silke Retlich is an author at Boehringer Ingelheim (Germany) specializing in pharmacokinetics, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	140
2	Pharmacology	3	3	140
3	Biochemistry	2	2	92
4	Diabetes	2	2	92
5	Clinical Pharmacology	1	1	48

Silke Retlich

Publications

527

Citations

H-Index

Page 1

	Year	Citations
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin <sup>*</sup> Ulrike Graefe‐Mody, Christian Friedrich, Andreas Port, Diabetes Obesity and Metabolism	2011	185
Pharmacokinetics of linagliptin in subjects with hepatic impairment Ulrike Graefe‐Mody, Peter W. Rose, Silke Retlich, British Journal of Clinical Pharmacology	2012	76
Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects Silke Retlich, Vincent Duval, Arne Ring, Clinical Pharmacokinetics Molecular PharmacologyTherapeutic Drug MonitoringPharmacokinetic ModelingPharmacological StudyMedicine	2010	48
Binding to dipeptidyl peptidase‐4 determines the disposition of linagliptin (BI 1356) – investigations in DPP‐4 deficient and wildtype rats Silke Retlich, B. Withopf, Andreas Greischel, Biopharmaceutics & Drug Disposition Molecular PharmacologyNeuropeptidesSignal TransductionPharmacological StudyBiochemistry	2009	46
Impact of Target‐Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP‐4 Inhibition in Type 2 Diabetic Patients Silke Retlich, Vincent Duval, Ulrike Graefe‐Mody, The Journal of Clinical Pharmacology Diabetes ManagementInhibitor LinagliptinPharmacokinetic ModelingBiochemistryPharmacological Study	2010	46
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus Jorge Luiz Gross, James A. Rogers, Daniel Polhamus, BMJ Open	2013	34
Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes Kyle Baron, Sreeraj Macha, Uli C. Broedl, Diabetes Therapy	2016	23
Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes William V. Tamborlane, Lori M. Laffel, Jacques Weill, Pediatric Diabetes	2017	20
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus Silke Retlich, Vincent Duval, Ulrike Graefe‐Mody, Clinical Pharmacokinetics	2015	19
Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus Christian Friedrich, Stephan Glund, Dominick A. Lionetti, British Journal of Clinical Pharmacology	2013	18

Page 1